Treace Medical Concepts Inc (TMCI)

Featured in High-Beta Stocks

Treace Medical Concepts, Inc. is a healthcare equipment and supplies company focused on medical technology for bunion and related foot deformity correction. The company develops, manufactures, and markets a portfolio of surgical systems and instruments in the United States. Its offerings include the Lapiplasty System, which is designed to correct bunion deformity in three dimensions and stabilize the first TMT joint, along with minimally invasive solutions such as Nanoplasty 3D and Percuplasty. Treace also provides products for other foot and midfoot conditions, including the Adductoplasty System, SpeedMTP, SpeedPlate implant platforms, and SpeedAkin. In addition, the company sells patient-specific planning and instrumentation tools, release and contouring instruments, and biologics and wedges used in surgical procedures. Treace Medical Concepts was founded in 2013 and is headquartered in Ponte Vedra, Florida.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-TMCI
$5.64
33.1% Upside
Undervalued
$4.67
10.1% Upside
Fair
Fair
0.0%
August 11, 2026
-4.5x
3.6x
1.3x
274.4 M
297.4 M
20.7%
73.7%
0.1
42.5%
Valuation • Fair Value

Treace Medical Concepts Inc (NASDAQ-TMCI) Fair Value by Valuation Model

Compare the primary fair value estimate for Treace Medical Concepts Inc (NASDAQ-TMCI) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$5.64

Estimated upside of 33.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$5.12

Earnings power value estimate.

Comps Fair Value

$5.73

Comparable-company valuation reference.

Analyst Price Target

$4.67

Analysts imply upside of 10.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Treace Medical Concepts Inc (NASDAQ-TMCI) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Treace Medical Concepts Inc (NASDAQ-TMCI)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

207.3 M

Current operating scale indicator.

Revenue Forecast

206.7 M

Forward revenue estimate.

EBITDA

-47.678 M

Current operating profitability reference.

EBITDA Forecast

-5.75 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Treace Medical Concepts Inc (NASDAQ-TMCI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Treace Medical Concepts Inc (NASDAQ-TMCI)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-3.71

No elevated caution signal from this screen.

Altman Z-Score

0.1

Lower score that deserves closer risk review.

FCF / Net Income

42.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Treace Medical Concepts Inc (NASDAQ-TMCI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Treace Medical Concepts Inc (NASDAQ-TMCI)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 11, 2026

Days to Earnings

21

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Treace Medical Concepts Inc (NASDAQ-TMCI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Treace Medical Concepts Inc (NASDAQ-TMCI) Stock Forecast & Technical Outlook

Review Treace Medical Concepts Inc (NASDAQ-TMCI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Treace Medical Concepts Inc (NASDAQ-TMCI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Treace Medical Concepts Inc (NASDAQ-TMCI) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Treace Medical Concepts Inc (NASDAQ-TMCI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Treace Medical Concepts Inc (NASDAQ-TMCI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Treace Medical Concepts Inc (NASDAQ-TMCI) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Treace Medical Concepts Inc (NASDAQ-TMCI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Treace Medical Concepts Inc (NASDAQ-TMCI) has a Hold consensus, with 1 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 3
Sell 0
FAQ Fast Investor Answers

Treace Medical Concepts Inc (NASDAQ-TMCI) Stock FAQ

Quick answers about Treace Medical Concepts Inc (NASDAQ-TMCI) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$5.64
Estimated upside 33.1%
Valuation Rating
Undervalued
Estimated upside of 33.1%
Analyst Target
$4.67
Implied upside 10.1%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Treace Medical Concepts Inc (NASDAQ-TMCI) is $5.64. This implies an estimated upside of 33.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 33.1% versus the current market price.

The available analyst price target for Treace Medical Concepts Inc (NASDAQ-TMCI) is $4.67. The analyst target implies estimated upside of 10.1%.

The current financial health read for Treace Medical Concepts Inc (NASDAQ-TMCI) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Treace Medical Concepts Inc (NASDAQ-TMCI) is August 11, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Treace Medical Concepts Inc (NASDAQ-TMCI) is -4.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Treace Medical Concepts Inc is 274.4 M.

The current enterprise value listed for Treace Medical Concepts Inc is 297.4 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Treace Medical Concepts Inc is NASDAQ-TMCI, and the stock is listed on NASDAQ.

Treace Medical Concepts Inc (NASDAQ-TMCI) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Treace Medical Concepts Inc is 20.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Treace Medical Concepts Inc is 73.7%. Free float helps investors understand how much of the share base is available for public trading.